Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma

Hepatology Research

Volumn 46, Issue 11, 2016, Pages 1145-1151

  Hirotsu, Yosuke ^a   Zheng, Tang Hui ^c   Amemiya, Kenji ^a   Mochizuki, Hitoshi ^a   Guleng, Bayasi ^c   Omata, Masao ^a,b  

^a Yamanashi Prefectural Central Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

CTNNB1; hepatocellular carcinoma; next generation sequencing; TP53; tumor

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN; MUTANT PROTEIN; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; AXON; BLOOD; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; EXOME; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; SLIT3 GENE; SOMATIC MUTATION; TP53 GENE; WNT SIGNALING PATHWAY;

EID: 84991044084     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12663     Document Type: Article

References (34)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245–55.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264–73.
4. El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 2007; 132: 2557–76.
5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339–46.
6. Tateishi R, Omata M. Hepatocellular carcinoma in 2011: Genomics in hepatocellular carcinoma—a big step forward. Nat Rev Gastroenterol Hepatol 2012; 9: 69–70.
7. Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 2014; 11: 340–9.
8. Nakagawa H, Shibata T. Comprehensive genome sequencing of the liver cancer genome. Cancer Lett 2013; 340: 234–40.
9. Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 760–4.
10. Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694–8.
11. Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014; 46: 1267–73.
12. Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013; 23: 1422–33.
13. Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43: 828–9.
14. Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013; 4: 1–6.
15. Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med 2015; 3: 121–9.
16. Hirotsu Y, Nakagomi H, Sakamoto I, et al. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. Mol Genet Genomic Med 2015. DOI:http://dx.doi.org/10.1002/mgg3.157.
17. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43: D805–11.
18. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073–81.
19. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248–9.
20. Thomas PD, Kejariwal A. Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: evolutionary evidence for differences in molecular effects. Proc Natl Acad Sci U S A 2004; 101: 15 398–403.
21. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. Computational approaches for predicting the biological effect of p53 missense mutations: A comparison of three sequence analysis based methods. Nucleic Acids Res 2006; 34: 1317–25.
22. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607–14.
23. Xu J, Reumers J, Couceiro JR, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285–95.
24. Jagosova J, Pitrova L, Slovackova J, Ravcukova B, Smarda J, Smardova J. Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells. Int J Oncol 2012; 41: 1157–63.
25. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443–54.
26. Liu C, Li Y, Semenov M, et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837–47.
27. Valenta T, Hausmann G, Basler K. The many faces and functions of β-catenin. EMBO J 2012; 31: 2714–36.
28. Provost E, McCabe A, Stern J, Lizardi I, D'Aquila TG, Rimm DL. Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene 2005; 24: 2667–76.
29. Cancer P, Project G. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399–405.
30. Wong CM, Fan ST, Ng IOL. b-catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer 2001; 92: 136–45.
31. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. P53 Gene Mutation Spectrum in Hepatocellular Carcinoma. Cancer Res 1992; 52: 6358–64.
32. Povero D, Busletta C, Novo E, et al. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 2010; 25: 1075–91.
33. Cooper CS, Eeles R, Wedge DC, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015; 47: 367–72.
34. Martincorena I, Roshan A, Gerstung M, et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015; 348: 880–7.